Alrestatin

Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.^[1][2]

Alrestatin

Names
Preferred IUPAC name (1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)acetic acid
Identifiers
CAS Number	51411-04-2
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL63055
ChemSpider	2036
KEGG	D02835
PubChem CID	2120
UNII	515DHK15LG
CompTox Dashboard (EPA)	DTXSID7045655
InChI InChI=1S/C14H9NO4/c16-11(17)7-15-13(18)9-5-1-3-8-4-2-6-10(12(8)9)14(15)19/h1-6H,7H2,(H,16,17) Key: GCUCIFQCGJIRNT-UHFFFAOYSA-N InChI=1/C14H9NO4/c16-11(17)7-15-13(18)9-5-1-3-8-4-2-6-10(12(8)9)14(15)19/h1-6H,7H2,(H,16,17) Key: GCUCIFQCGJIRNT-UHFFFAOYAQ
SMILES C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CC(=O)O
Properties
Chemical formula	C14H9NO4
Molar mass	255.229 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Alrestat was first synthesized in 1969 and was the first aldose reductase inhibitor (ARI) with oral bioavailability to undergo clinical trials, in the late 1970s and early 1980s. Low-quality trials and a high incidence of adverse effects (particularly hepatotoxicity) led to termination of its development, and it was never in clinical use.^[3][4] It is structurally related to tolrestat, another ARI that was briefly marketed before being withdrawn in 1997.

Synthesis

Alrestatin can be synthesized by the reaction of naphthalic anhydride with glycine.^[5]

Alrestatin synthesis

See also

• Amonafide
• Scriptaid